prostate cancer
CHICAGO, IL-Sipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be presented April 28 at the American Urological Association (AUA) Annual Scientific Meeting in Chicago.
LINTHICUM, MD, April 27, 2009--The American Urological Association (AUA) today issued new clinical guidance - which directly contrasts recent recommendations issued by other major groups - about prostate cancer screening, asserting that the prostate-specific antigen (PSA) test should be offered to well-informed, men aged 40 years or older who have a life expectancy of at least 10 years.
A protein shown to be present in prostate cancer cells can inhibit the growth of tumours. Called the SOCS-1 protein, it belongs to the SOCS (suppressor of cytokine signalling) class of proteins. These produce very different effects depending on the type of tumour.
Prostate cancer patients who undergo therapy to decrease testosterone levels increase their risk of developing bone- and heart-related side effects compared to patients who do not take these medications, according to a new analysis.
The following tips are on abstracts or posters to be presented at the American Urological Association Annual Meeting 2009, April 25-30, or the concurrent Engineering & Urology Society Annual Meeting 2009, April 25, Chicago, Ill.
GIVING PROSTATE CANCER THE COLD SHOULDER
--"Cold shock" proteins could be new target in cancer fight
DURHAM, N.C. - Cholesterol-lowering drugs called statins may reduce inflammation in prostate tumors, possibly hindering cancer growth, according to a study led by investigators in the Duke Prostate Center.
LINTHICUM, MD, April 26, 2009-Active surveillance may be a viable option for some men, but reclassification of disease risk over time is imperative to ensure outcomes, according to researchers in Toronto, who will present these criteria during the 104th Annual Scientific Meeting of the American Urological Association (AUA).
LINTHICUM, MD, April 26, 2009-Pomegranate juice may slow the progression of post-treatment prostate cancer recurrence, according to new long-term research results being presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA).
LINTHICUM, MD, April 26, 2009-The combination therapy of vitamin E, selenium and soy does not prevent the progression from high-grade prostatic intraepithelial neoplasia (HGPIN) to prostate cancer, according to the new research presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA).
Survival rates for cancer are continuing to rise even though the number of cases being diagnosed is increasing, an all-Ireland report launched today reveals.
Shirly Sieh, a PhD student at IHBI, is studying the way cancer cells escape from the prostate through the bloodstream to form tumour colonies, most often in the spine and long bones.
Notch1 Contributes to Scar Tissue in the Lungs
A group led by Dr. Sem Phan at the University of Michigan, Ann Arbor identified Notch1 as a mediator of lung fibrosis. They present their data in the May 2009 issue of The American Journal of Pathology.
In patients with prostate cancer undergoing prostatectomy, MR imaging plays an important role in determining if the cancer is restricted to the prostate gland or if it has spread beyond the capsule, according to a study performed at the University of California, Los Angeles, Los Angeles, CA.
Finally some promising news about pancreatic cancer, one of the most fatal cancers, due to the difficulties of early detection and the lack of effective therapies: Johns Hopkins University pathologist Akhilesh Pandey has identified an epidermal growth factor receptor aberrantly active in approximately a third of the 250 human pancreatic cancers studied.
One cell...one initial set of genetic changes - that's all it takes to begin a series of events that lead to metastatic cancer. Now, Johns Hopkins experts have tracked how the cancer process began in 33 men with prostate cancer who died of the disease.
